ValuEngine upgraded shares of Edge Therapeutics (NASDAQ:EDGE) from a hold rating to a buy rating in a research report report published on Thursday.
Shares of Edge Therapeutics stock traded down $0.01 during midday trading on Thursday, hitting $0.70. The company’s stock had a trading volume of 417,573 shares, compared to its average volume of 319,676. Edge Therapeutics has a 1-year low of $0.68 and a 1-year high of $17.77.
Edge Therapeutics (NASDAQ:EDGE) last released its quarterly earnings data on Thursday, November 1st. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.16.
About Edge Therapeutics
Edge Therapeutics, Inc, a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Its lead product includes EG-1962, a polymer-based microparticle used for the treatment of aneurysmal subarachnoid hemorrhage.
Featured Article: Dollar Cost Averaging
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.